DRUG TREATMENT PLANS DERIVED FROM HOLISTIC ANALYSIS

• US 20120078601A1
• Filed: 09/26/2011
• Published: 03/29/2012
• Est. Priority Date: 09/27/2010
• Status: Abandoned Application

• Current Assignee: General Electric Company
• Original Assignee: General Electric Company
• Inventors: Avinash, Gopal B., Mohan, Ananth P., Lin, Zhongmin S., Wascher, Rick R.
• Application Number:
  US13/245,512
• Publication Number:
  US 20120078601A1
• Time in Patent Office: Days
• US Class Current: 703/11
• CPC Class Codes: G16H 50/70 for mining of medical data, e.g. analysing previous cases of other patients

Abstract

Certain examples provide systems and methods for holistic viewing to provide comparative analysis and patient treatment decision support in a drug therapy development process. A computer-implemented method for developing a therapeutic drug treatment plan for a patient using quantifiable comparative holistic decision support. In addition, the inventive may also be summarized as a computer-implemented method for developing a therapeutic drug treatment plan for a patient using quantifiable comparative holistic decision support for a known disease signature corresponding to a subject medical condition of a patient.

Claims

1. A computer-implemented method for developing a therapeutic drug treatment plan for a patient using quantifiable comparative holistic treatment decision support, said method comprising:

accessing a disease signature corresponding to a patient'"'"'s known medical condition;

accessing a subject drug performance data set related to the performance of a subject drug with respect to the known medical condition;

accessing a reference set of drug performance data related to the performance of the subject drug with respect to the known medical condition found within a group of patients;

holistically determining the medical differences between the subject drug performance data set and reference drug performance data set and generating a third data set of projected medical outcome data corresponding to the medical condition; and

developing a drug treatment plan for the patient based on the projected medical outcome data.

2. The method of claim 1 wherein:

the medical condition includes any number of known disease signatures and the treatment plan corresponds to at least one of the known disease signatures associated with the medical condition.

3. The method of claim 2, further comprising:

iterative holistic determination of the medical differences between the subject drug performance data set and reference drug performance data set and selection of a preferred known disease signature.

4. The method of claim 3 wherein the iterative development further comprises:

a reference drug performance data set is obtained by conducting in vitro testing.

5. The method of claim 3 wherein the iterative development further comprises:

a reference drug performance data set is obtained by conducting in vivo testing.

6. The method of claim 4 wherein the iterative development further comprises:

a reference drug performance data set is obtained by conducting clinical trials of the reference drug.

7. The method of claim 3 wherein the iterative development further comprises:

repetitively accessing any number of reference drug performance data sets for generating the third data set.

8. The method of claim 7 wherein the iterative development further comprises:

repetitively developing a drug treatment plan for each disease signature.

9. The method of claim 8 wherein the iterative development further comprises:

repetitively developing a drug treatment plan for subject drug.

10. The method of claim 8 wherein the repetitively developing a drug treatment plan for each disease signature further comprises:

comparing each of the drug treatment plans to reference set of drug performance data for the group.

11. A computer-implemented method for developing a therapeutic drug treatment plan for a patient using quantifiable comparative holistic treatment decision support for a known disease signature corresponding to a subject medical condition of a patient, said method comprising:

accessing a subject drug performance data set related to the performance of the subject drug with respect to the known disease signature;

accessing a reference set of drug performance data related to the performance of the subject drug with respect to the disease signature found within at least one medical condition a reference group of patients;

holistically determining the medical differences between the medical conditions of the reference drug performance data sets and the subject drug performance data set, and generating a third data set of projected medical outcome data corresponding to the medical condition of a subject patient not within the reference group; and

developing a drug treatment plan for the patient based on the projected medical outcome data.

12. The method of claim 11 wherein:

the medical condition of the subject patient includes any number of known disease signatures and the treatment plan corresponds to at least one of the known disease signatures associated with their medical condition.

13. The method of claim 12, further comprising:

iterative holistic determination of the medical differences between the subject drug performance data set and reference drug performance data set and selection of a subject drug.

14. The method of claim 13 wherein the iterative development further comprises:

a reference drug performance data set is obtained by conducting in vitro testing.

15. The method of claim 13 wherein the iterative development further comprises:

a reference drug performance data set is obtained by conducting in vivo testing.

16. The method of claim 14 wherein the iterative development further comprises:

a reference drug performance data set is obtained by conducting clinical trials of the reference drug.

17. The method of claim 13 wherein the iterative development further comprises:

repetitively accessing any number of reference drug performance data sets for generating the third data set.

18. The method of claim 17 wherein the iterative development further comprises:

repetitively developing a drug treatment plan for each disease signature.

19. The method of claim 18 wherein the iterative development further comprises:

repetitively developing a drug treatment plan for subject drug.

20. The method of claim 18 wherein the repetitively developing a drug treatment plan for each disease signature further comprises:

comparing each of the drug treatment plans to reference set of drug performance data for the group.